Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
THTX 
Theratechnologies Inc. (THTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: THTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.98
1 Year Target Price $3.98
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.45% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 111.00M USD | Price to earnings Ratio - | 1Y Target Price 3.98 |
Price to earnings Ratio - | 1Y Target Price 3.98 | ||
Volume (30-day avg) 3 | Beta 0.89 | 52 Weeks Range 1.12 - 3.13 | Updated Date 07/1/2025 |
52 Weeks Range 1.12 - 3.13 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-08 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -4.18% | Operating Margin (TTM) 9.95% |
Management Effectiveness
Return on Assets (TTM) 11.98% | Return on Equity (TTM) -1116.86% |
Valuation
Trailing PE - | Forward PE 55.87 | Enterprise Value 154975335 | Price to Sales(TTM) 1.25 |
Enterprise Value 154975335 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 15.31 | Shares Outstanding 45980000 | Shares Floating 35901659 |
Shares Outstanding 45980000 | Shares Floating 35901659 | ||
Percent Insiders 1.15 | Percent Institutions 47.7 |
Analyst Ratings
Rating 1 | Target Price 3.98 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Theratechnologies Inc.
Company Overview
History and Background
Theratechnologies Inc. is a specialty pharmaceutical company that was founded in 1993. It focuses on the development and commercialization of therapies addressing unmet medical needs, including those related to HIV and oncology.
Core Business Areas
- HIV: Theratechnologies develops and commercializes therapies to address the health challenges of people living with HIV. Its main drug is Trogarzo.
- Oncology: The company is expanding into oncology with its product Tesamorelin (Egrifta), which it is exploring for various cancer-related indications.
Leadership and Structure
Luc Tanguay is the President and Chief Executive Officer. The company has a Board of Directors providing oversight and governance.
Top Products and Market Share
Key Offerings
- Trogarzo (ibalizumab-uiyk): Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. It is used in combination with other antiretrovirals for HIV-1 infected adults with multi-drug resistance. Competitors include other antiretroviral drug combinations; market share data not publicly available at this granular level. Trogarzo's revenue are the company's main revenue generator.
- Egrifta (tesamorelin): Egrifta is a growth hormone-releasing factor (GHRF) analog indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies is currently testing Egrifta's analog for Oncology treatments. Potential competitors include other treatments for lipodystrophy and other future similar therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and patient demand. The HIV treatment market continues to evolve with new therapies focused on improved efficacy and patient convenience. The oncology market is vast and highly competitive.
Positioning
Theratechnologies is positioned as a specialty pharmaceutical company with expertise in HIV and a growing presence in oncology. Its competitive advantage lies in its niche products targeting specific patient populations.
Total Addressable Market (TAM)
The global HIV therapeutics market is estimated to be tens of billions of dollars, and the global oncology market is several hundred billion dollars. Theratechnologies is positioned to capture a portion of these markets with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Specialized expertise in HIV therapies
- Approved and marketed products (Trogarzo and Egrifta)
- Expanding pipeline in oncology
- Established distribution network for HIV products
Weaknesses
- Reliance on a limited number of products
- Smaller market capitalization compared to major pharmaceutical companies
- Potential for generic competition
- High R&D costs
Opportunities
- Expanding indications for existing products
- Acquiring or licensing new therapies
- Geographic expansion into new markets
- Strategic partnerships with larger pharmaceutical companies
Threats
- Competition from larger pharmaceutical companies
- Changes in regulatory landscape
- Pricing pressures from payers
- Patent expirations
Competitors and Market Share
Key Competitors
- GILD
- VTRS
- MRK
- JNJ
Competitive Landscape
Theratechnologies faces intense competition from larger pharmaceutical companies with greater resources. Its niche products provide a competitive advantage, but sustained growth depends on successful pipeline development and commercial execution.
Growth Trajectory and Initiatives
Historical Growth: Data not available without live data access.
Future Projections: Analyst estimates suggest continued growth in revenue driven by Trogarzo and potential success in oncology.
Recent Initiatives: Focusing on clinical trials for Tesamorelin in oncology, expanding commercial reach for Trogarzo, and managing expenses.
Summary
Theratechnologies is a specialty pharmaceutical company focused on HIV and oncology. While it has approved products and growth potential, it faces competition from larger firms. Future success depends on pipeline advancement and strategic partnerships. High reliance on only a few products and significant competition, make it a very challenging company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theratechnologies Inc.
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Paul Lévesque | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.theratech.com |
Full time employees - | Website https://www.theratech.com | ||
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.